and have , 100mg/mL injection for intravenous use, from the US Food and Drug Administration (FDA) under the Accelerated Approval Pathway to treat Alzheimer鈥檚 disease (AD).
Leqembi is indicated to treat mild cognitive impairment or mild dementia stage of the disease in patients whose treatment started in clinical trials.
The humanised immunoglobulin gamma 1 (IgG1) monoclonal antibody, Leqembi is directed against aggregated soluble (protofibril) and insoluble amyloid-beta (A尾) forms.
The regulatory approval is based on the data obtained from the Phase II trial.
In the trial, Leqembi minimised the A脽 plaque accumulation in the brain, which is said to be a defining feature of AD.
CEO Haruo Naito said: 鈥淭he FDA鈥檚 approval of Leqembi under the Accelerated Approval pathway is an important milestone in Eisai鈥檚 four decades of research in Alzheimer鈥檚 disease and reflects our continued commitment to alleviating the burden of Alzheimer鈥檚 disease for patients and their families.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData鈥淓isai has made great efforts to understand the reality of the challenges and concerns facing patients and their families who are living in the various stages of Alzheimer鈥檚 disease, and we are incredibly pleased to offer Leqembi as a new treatment option to help with the tremendous unmet needs of this community.鈥�
The company estimates that the number of US patients eligible for Leqembi would reach around 100,000 in three years, increasing gradually over the mid-to-long term.
In a separate development, Eisai has submitted a supplemental Biologics License Application (sBLA) to the US FDA for traditional approval of Leqembi.
The regulatory submission was based on the data obtained from the Phase III confirmatory Clarity AD clinical trial.
Leqembi met the primary endpoint and all the critical secondary endpoints in the Clarity AD trial.
The Amyloid-Related Imaging Abnormalities (ARIA) incidence profile of Leqembi was within expectations.
